Recent Updates
Recently added Catalysts
MDAI Positive Sentiment Score: 75/100

Spectral AI Comments on Compliance with Nasdaq Listing Rule 5550(b)(2)

Key Takeaway: Spectral AI has announced that it believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2) after its market value exceeded $35 million for 10 consecutive business days. The company is awaiting confirmation from Nasdaq regarding this compliance. Spectral AI's DeepView® System, which uses AI for predicting burn healing potential, continues to focus on enhancing treatment decisions in wound care, particularly for burns and diabetic foot ulcers.

Market Sentiment Analysis

POSITIVE FACTORS

  • Spectral AI has regained compliance with Nasdaq Listing Rule 5550(b)(2).
  • The company's market value has exceeded $35 million for 10 consecutive days.
  • DeepView® System aims to improve patient outcomes and reduce healthcare costs.

Full Press Release Details

DALLAS, Dec. 13, 2024 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. FDA in 2018, that uses multi-spectral imaging and algorithms to predict burn healing potential, today announced today that the Company believes it has regained compliance with Nasdaq Listing Rule 5550(b)(2), which requires listed companies to maintain a minimum market value of listed securities of $35 million.
The market value of Spectral AI’s common stock has exceeded $35 million at the close of trading for the last 10 consecutive business days, as required by Nasdaq rules. The company has notified Nasdaq of its compliance and is awaiting confirmation from the exchange.
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView is a predictive device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, DeepView is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView, visit www.spectral-ai.com.
Forward-Looking Statements
Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s intention to separate its Spectral IP subsidiary from the Company, and each Company’s strategy, plans, objectives, initiatives, strategic goals, financial outlook or other non-historical matters. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.
These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.
Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Spectral AI undertakes no obligation to update any forward-looking statements except as otherwise required by law.
For Media and Investor Relations, please contact:
Atlanta Capital Partners LLC
(866) 692-6847 Toll Free - U.S. & Canada
(404) 281-8556 Mobile and WhatsApp

Tags

Frequently Asked Questions

What is the DeepView® System?

The DeepView® System is an AI-driven device by Spectral AI that uses multi-spectral imaging to predict burn healing potential.

Has Spectral AI met Nasdaq listing requirements?

Yes, Spectral AI exceeded a market value of $35 million for 10 consecutive business days, regaining compliance.

What conditions does DeepView® target?

DeepView® focuses on improving treatment decisions for burns and diabetic foot ulcers.

How does DeepView® improve patient care?

DeepView® aims to provide faster, more accurate healing assessments to enhance patient outcomes.

Where can I learn more about DeepView®?

More information about DeepView® is available at www.spectral-ai.com.

Last updated: Dec 13, 2024